Biophytis SA (FR:ALBPS) has released an update.
Biophytis SA has received FDA approval to commence a phase 2 clinical study of BIO101 for obesity, focusing on muscle strength and mobility improvements. Anticipated to start in mid-2024 in the USA, the study’s prelim results are expected in 2025. The company is actively seeking funding and partnerships to advance this study in the growing obesity treatment market.
For further insights into FR:ALBPS stock, check out TipRanks’ Stock Analysis page.
